Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Colorectal Neoplasms

  Free Subscription


05.02.2024

1 Am J Surg
1 Ann Oncol
2 Ann Surg Oncol
6 Anticancer Res
4 BMC Cancer
1 BMC Gastroenterol
2 Br J Cancer
3 Br J Surg
2 Cancer
2 Cancer Lett
1 Clin Cancer Res
2 Eur J Cancer
2 Gastroenterology
1 Int J Colorectal Dis
1 J Am Coll Surg
1 Lancet Oncol
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg

  1. FICARINO H, Cage B, Osula JP, Heatherly A, et al
    Deficiencies in germline genetic testing in young-onset colorectal cancer patients.
    Am J Surg. 2024 Jan 26:S0002-9610(24)00025-4. doi: 10.1016/j.amjsurg.2024.
    PubMed         Abstract available


    Ann Oncol

  2. SANTUCCI C, Mignozzi S, Malvezzi M, Boffetta P, et al
    European cancer mortality predictions for the year 2024 with focus on colorectal cancer.
    Ann Oncol. 2024 Jan 17:S0923-7534(23)05110-4. doi: 10.1016/j.annonc.2023.
    PubMed         Abstract available


    Ann Surg Oncol

  3. GRANGE R, Rousset P, Williet N, Guesnon M, et al
    ASO Visual Abstract: Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence.
    Ann Surg Oncol. 2024 Jan 29. doi: 10.1245/s10434-024-14923.
    PubMed        

  4. BEKKI T, Shimomura M, Hattori M, Sato S, et al
    C-Reactive Protein/Albumin Ratio Is an Independent Risk Factor for Recurrence and Survival Following Curative Resection of Stage I-III Colorectal Cancer in Older Patients.
    Ann Surg Oncol. 2024 Jan 27. doi: 10.1245/s10434-024-14961.
    PubMed         Abstract available


    Anticancer Res

  5. OGAWA H, Shiraishi T, Okada T, Miyamae Y, et al
    Adjuvant Chemotherapy With UFT/LV Versus UFT/LV Plus PSK in Stage II/III Colorectal Cancer.
    Anticancer Res. 2024;44:805-814.
    PubMed         Abstract available

  6. NAKAMURA S, Kageyama H, Torii K, Hishida M, et al
    High-risk Features for Recurrence in Patients With Stage III Colorectal Cancer: A Retrospective Cohort Study.
    Anticancer Res. 2024;44:757-766.
    PubMed         Abstract available

  7. NONAKA K, Nakanishi R, Nambara S, Jiang HQ, et al
    Clinicopathological Impact of High Preoperative CA19-9 in Early-stage Colorectal Cancer: A Single-center Retrospective Cohort Study.
    Anticancer Res. 2024;44:797-803.
    PubMed         Abstract available

  8. ZHENG H, Tsunedomi R, Xu M, Zhang Y, et al
    Effect of Paxillin Expression and Phosphorylation on Colorectal Cancer Prognosis and Metastasis.
    Anticancer Res. 2024;44:511-520.
    PubMed         Abstract available

  9. YAMAMOTO A, Shimizu H, Takiguchi K, Shoda K, et al
    The Expression and Role of Aquaporin 4 in Colon Cancer.
    Anticancer Res. 2024;44:567-573.
    PubMed         Abstract available

  10. NAKAYAMA T, Furuya S, Higuchi Y, Matsuoka K, et al
    Investigating Cytoglobin Expression in Colon Cancer: Clinicopathological Insights from Immunohistochemical Analysis.
    Anticancer Res. 2024;44:561-565.
    PubMed         Abstract available


    BMC Cancer

  11. GEHR NL, Karlsson P, Timm S, Christensen S, et al
    Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    BMC Cancer. 2024;24:168.
    PubMed         Abstract available

  12. FURUYA K, Nakajima M, Tsunedomi R, Nakagami Y, et al
    High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
    BMC Cancer. 2024;24:165.
    PubMed         Abstract available

  13. LIAO L, Tang J, Hong Z, Jiang W, et al
    The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    BMC Cancer. 2024;24:164.
    PubMed         Abstract available

  14. MEHRJOEI B, Haghnazari L, Bashiri H, Rezvani N, et al
    The diagnostic potential of miR-196a-1 in colorectal cancer.
    BMC Cancer. 2024;24:162.
    PubMed         Abstract available


    BMC Gastroenterol

  15. SONG Y, Mao Q, Zhou M, Liu CJ, et al
    Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis.
    BMC Gastroenterol. 2024;24:58.
    PubMed         Abstract available


    Br J Cancer

  16. FATIMA I, Ahmad R, Barman S, Gowrikumar S, et al
    Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20.
    Br J Cancer. 2024 Jan 26. doi: 10.1038/s41416-023-02570.
    PubMed         Abstract available

  17. SHAH ET, Molloy C, Gough M, Kryza T, et al
    Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.
    Br J Cancer. 2024 Jan 29. doi: 10.1038/s41416-024-02584.
    PubMed         Abstract available


    Br J Surg

  18. BILKHU AS, Wild J, Sagar PM
    Management of retrorectal tumours.
    Br J Surg. 2024;111:znae012.
    PubMed        

  19. KELM M, Flemming S
    Comment on: Early outcomes from the Minimally Invasive Right Colectomy Anastomosis Study (MIRCAST).
    Br J Surg. 2024;111:znad440.
    PubMed        

  20. GOMEZ RUIZ M, Espin-Basany E, Spinelli A, Cagigas Fernandez C, et al
    Author response to: Comment on: Early outcomes from the Minimally Invasive Right Colectomy Anastomosis study (MIRCAST).
    Br J Surg. 2024;111:znad444.
    PubMed        


    Cancer

  21. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed         Abstract available

  22. RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al
    Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030.
    PubMed         Abstract available


    Cancer Lett

  23. ZHU J, Li J, Yang K, Chen Y, et al
    NR4A1 depletion inhibits colorectal cancer progression by promoting necroptosis via the RIG-I-like receptor pathway.
    Cancer Lett. 2024 Jan 30:216693. doi: 10.1016/j.canlet.2024.216693.
    PubMed         Abstract available

  24. TANG J, Lam GT, Brooks RD, Miles M, et al
    Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system.
    Cancer Lett. 2024 Jan 28:216639. doi: 10.1016/j.canlet.2024.216639.
    PubMed         Abstract available


    Clin Cancer Res

  25. STAHLER A, Kind AJ, Sers C, Mamlouk S, et al
    Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212).
    Clin Cancer Res. 2024 Jan 30. doi: 10.1158/1078-0432.CCR-23-3023.
    PubMed         Abstract available


    Eur J Cancer

  26. OSTERMAN E, Syriopoulou E, Martling A, Andersson TM, et al
    Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
    Eur J Cancer. 2024;199:113572.
    PubMed         Abstract available

  27. PASTORINO A, Catalano F, Zalcberg JR, Sobrero A, et al
    Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
    Eur J Cancer. 2024;199:113538.
    PubMed         Abstract available


    Gastroenterology

  28. YANG J, Wei H, Lin Y, Chu ESH, et al
    High Soluble Fiber Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites in Mice.
    Gastroenterology. 2024;166:323-337.
    PubMed         Abstract available

  29. YOUNG E, Rajagopalan A, Tee D, Sathananthan D, et al
    Texture and Color Enhancement Imaging Improves Colonic Adenoma Detection: A Multicenter Randomized Controlled Trial.
    Gastroenterology. 2024;166:338-340.
    PubMed         Abstract available


    Int J Colorectal Dis

  30. MARJASUO S, Koskenvuo L, Lepisto A
    Findings in magnetic resonance imaging for restaging locally advanced rectal cancer.
    Int J Colorectal Dis. 2024;39:23.
    PubMed         Abstract available


    J Am Coll Surg

  31. BANSAL VV, Belmont E, Godley Iv F, Dhiman A, et al
    Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
    J Am Coll Surg. 2024 Feb 1. doi: 10.1097/XCS.0000000000001028.
    PubMed         Abstract available


    Lancet Oncol

  32. FREI AL, McGuigan A, Sinha RRAK, Jabbar F, et al
    Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
    Lancet Oncol. 2024;25:198-211.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  33. YU Z, Deng P, Chen Y, Lin D, et al
    Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2304619121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.